rs9282858

This is a coding sequence variant variant in the SRD5A2 gene.

GWAS Catalog Trait Associations (7)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

X-11444 measurement

Allele T
OR 0.68
p 5.0e-66
N 8,206
Large GWAS
European
Allele T
OR 0.46
p 5.0e-14
N 4,894
Large GWAS
European

X-11470 measurement

Allele T
OR 0.59
p 7.0e-46
N 8,134
Large GWAS
European
Allele T
OR 0.46
p 7.0e-13
N 4,853
Large GWAS
European

alopecia

Hagenaars SP et al. Genetic prediction of male pattern baldness. Plos Genetics 13(2):e1006594 (2017)
Allele T
OR 0.16
p 2.0e-23
N 52,874
Large GWAS
European

androsterone glucuronide measurement

Allele T
OR 0.34
p 3.0e-20
N 7,980
Large GWAS
European

balding measurement

Allele T
OR 0.51
p 9.0e-18
N 22,518
Meta-analysisLarge GWAS
European

ClinVar annotation

Uncertain Significance★★★
8 submitters5 publications

3-Oxo-5 alpha-steroid delta 4-dehydrogenase deficiency (PPSH); SRD5A2 POLYMORPHISM; SRD5A2-related disorder

View on ClinVar →

Research that mentions this SNP (2)

Joint effects of inflammation and androgen metabolism on prostate cancer severity
AssociationN=1,090Rebbeck TR et al.(2008)· International Journal of Cancer

A case-control study of 1,090 Caucasian prostate cancer cases examined interactions between genes involved in androgen metabolism/inflammation and benign prostatic hyperplasia (BPH) history on prostate cancer severity. Significant interactions were observed with CYP3A43 P340A (rs680055) and BPH on both Gleason grade (OR=1.82, 95% CI: 1.15–2.87; interaction p=0.026) and tumor stage (OR=3.50, 95% CI: 1.21–10.17; interaction p=0.017), suggesting that androgen metabolism and inflammatory phenotypes act together in determining prostate cancer severity.

Traits studied:Benign prostatic hyperplasiaGleason gradeProstate cancer severityTumor stage
Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF‐1, and IGFBP‐3 and prostate cancer risk in African‐American men: The Flint Men's Health Study
AssociationN=473Aruna V. Sarma et al.(2008)· The Prostate

A population-based case-control study of 473 African-American men (131 prostate cancer cases, 342 controls) examined SNP associations in six genes involved in androgen and IGF-1 pathways. Significant associations were found between prostate cancer and CYP17 SNPs rs6163, rs6162, and rs743572, with heterozygotes showing decreased risk (P=0.0014, 0.0018, 0.0028). Suggestive evidence for association was found between IGF-1 SNP rs5742657 and prostate cancer (P=0.058 genotype; P=0.02 allelic test). No significant associations were observed for SNPs in CYP3A4, CYP19A1, SRD5A2, or IGFBP-3 genes.

Traits studied:Prostate cancer

About SRD5A2

This gene encodes a microsomal protein expressed at high levels in androgen-sensitive tissues such as the prostate. The encoded protein is active at acidic pH and is sensitive to the 4-azasteroid inhibitor finasteride. Deficiencies in this gene can result in male pseudohermaphroditism, specifically pseudovaginal perineoscrotal hypospadias (PPSH). [provided by RefSeq, Jul 2008]

View all SRD5A2 variants →

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…